Literature DB >> 2407333

Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy.

R Tandan1, R Taylor, D P DiCostanzo, K Sharma, T Fries, J Roberts.   

Abstract

Myasthenia gravis (MG) occurs in up to 44% of patients with thymoma. Thirty-three percent of these neoplasms are invasive but extrathoracic disease is rare. Recently, we saw a patient with MG and recurrent, metastasizing mixed lymphoepithelial thymoma, whose disease was resistant to combination chemotherapy and radiotherapy but who responded dramatically to treatment with daily glucocorticoids. Thus, therapy with daily glucocorticoids should be considered in the treatment of invasive or metastatic thymoma associated with MG, including when conventional surgery, radiotherapy, and chemotherapy have failed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407333     DOI: 10.1002/1097-0142(19900315)65:6<1286::aid-cncr2820650605>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Clinical and pathologic predictors of survival in patients with thymoma.

Authors:  K B Wilkins; E Sheikh; R Green; M Patel; S George; M Takano; M Diener-West; J Welsh; S Howard; F Askin; G B Bulkley
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

2.  Metastatic Thymoma-Associated Myasthenia Gravis: Favorable Response to Steroid Pulse Therapy Plus Immunosuppressive Agent.

Authors:  Guoyan Qi; Peng Liu; Huimin Dong; Shanshan Gu; Hongxia Yang; Yinping Xue
Journal:  Med Sci Monit       Date:  2017-03-09

Review 3.  The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Authors:  Liliana Montella; Margaret Ottaviano; Rocco Morra; Erica Pietroluongo; Pietro De Placido; Marianna Tortora; Chiara Sorrentino; Gaetano Facchini; Sabino De Placido; Mario Giuliano; Giovannella Palmieri
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.